Drug costs
Cell and gene therapies
We detail factors in Phase-3 clinical trial design that influence health insurance coverage decisions.
A look at the model’s benefits, limitations, and considerations for expansion.
What the CMS model will mean for patient access to breakthrough, high-cost treatment for sickle cell disease.
Leveraging clinical research, market monitoring, and claims analysis to estimate cost exposure.
Exploring the CGT pipeline, approvals, treatment rate, and more.
Gene therapies, CAR T-cell therapies, and other innovative (and potentially curative) therapies are beginning to enter the market, and are making waves with their record-setting prices.
Gene therapies for rare diseases may offer a life-changing treatment option for some patients, but can payers keep up with the cost?
